Status:
UNKNOWN
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
Lead Sponsor:
Keymed Biosciences Co.Ltd
Conditions:
Moderate-to-severe Atopic Dermatitis
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of CM326 in moder...
Detailed Description
The study consists of 3 periods, a up-to-4-week Screening Period, a 12-week randomized Treatment Period and a 12-week Safety Follow-up Period.
Eligibility Criteria
Inclusion
- With confirmed Atopic Dermatitis (AD) at least 12 months before the screening
- Eczema Area and Severity Index (EASI) score ≥16 at screening and baseline
- Investigator's Global Assessment (IGA) score ≥3 at screening and baseline
- Body Surface Area (BSA) of involvement of atopic dermatitis ≥10% at screening and baseline
- The weekly mean score of daily peaks in pruritus NRS at baseline ≥4
- Provide signed informed consent
Exclusion
- Not enough washing-out period for previous therapy.
- Presence of other concomitant and poorly controlled serious diseases or recurrent chronic diseases, including but not limited to active infections, cardiovascular and cerebrovascular diseases, pulmonary tuberculosis or other pathogen infections, diabetes mellitus, autoimmune diseases, human immunodeficiency virus (HIV) infection, active hepatitis B, hepatitis C or parasitosis, neoplasm malignant, etc.
- Patients with severe hepatic or renal impairment, characterized by aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level \> 2 times of upper limit of normal (ULN), total bilirubin \>1.5 times of upper limit of normal (ULN) or serum creatinine level \> upper limit of normal (ULN).
- Womens who are pregnant or breastfeeding, or who plan to become pregnant during the study.
Key Trial Info
Start Date :
February 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT05186922
Start Date
February 17 2022
End Date
January 1 2023
Last Update
March 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's hospital
Beijing, Beijing Municipality, China